Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Immacolata Attolico, Paolo Sportoletti, Marco Cerrano, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Giuseppe Saglio, Gianantonio Rosti

Blood (2023) 142 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2023-180131

Published: 2023

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Carla Minoia, Davide Bavaro, Giacomo Loseto, Crescenza Pasciolla, Lucia Diella, Carmen Pelligrino, Valentina Totaro, Vito Spada, Michele Camporeale, Immacolata Attolico, Tommasina Perrone, Felice Clemente, Francesco di Gennaro, Pellegrino Musto, Attilio Guarini, Annalisa Saracino

Blood (2022) 140 (Supplement 1): 10967–10968.

https://doi.org/10.1182/blood-2022-168809

Published: 2022

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

JAK2 Negative Erythrocytosis Associated with JAK2 GGCC_46/1 Haplotype, Calr rs1049481_G, and Normal Erythropoietin Level: Is This a New Entity?

Antonella Zagaria, Francesco Tarantini, MD, Luisa Anelli, Paola Orsini, Angela Minervini, Nicoletta Coccaro, Elisa Parciante, Crescenzio Francesco Minervini, Cosimo Cumbo, Giuseppina Tota, Luciana Impera, Maria Rosa Conserva, Immacolata Redavid, Alessandra Ricco, MD, Immacolata Attolico, MD, Giorgina Specchia, MD, Pellegrino Musto, MD, Francesco Albano

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139450

Published: 2020

Journal Articles

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141077

Published: 2020

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Blood (2013) 122 (21): 1974.

https://doi.org/10.1182/blood.V122.21.1974.1974

Published: 2013

Journal Articles

Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Michele Pizzuti, Alberto Santagostino, Giuseppina Smaldore, Ida Chitarrelli, Domenico Vertone, Sara Pasquina Pascale, Angela Matturro, Immacolata Attolico, Angela Amendola, Michele Cimminiello, Nunzio Filardi, Antonella Girardi, Romina Penitente, Roberta Nuccorini, Sabrina Coluzzi, Enza Scavone

Blood (2013) 122 (21): 5314.

https://doi.org/10.1182/blood.V122.21.5314.5314

Published: 2013

Journal Articles

Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Michele Pizzuti, Alberto Santagostino, Maria Antonietta Rizzo, Daniela Dragonetti, Maria Grazia Pietrafesa, Immacolata Attolico, Angela Amendola, Nunzio Filardi, Michele Cimminiello, Angela Matturro, Domenico Vertone, Roberta Nuccorini, sara Pasquina Pascale, Sabrina Coluzzi

Blood (2013) 122 (21): 4798.

https://doi.org/10.1182/blood.V122.21.4798.4798

Published: 2013

Journal Articles

Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning

Immacolata Attolico, Roberta Nuccorini, Alberto Fragasso, Vincenzo Pavone, Pellegrino Musto, Silvana Capalbo, MD, Gaetano Palumbo, MD, Giorgina Specchia, Cristiana Carniti, PhD, Paolo Corradini, MD, Sara Pascale, Sabrina Coluzzi, Michele Pizzuti, Angela Amendola, Michele Cimminiello, Angela Matturro, Domenico Vertone, Nunzio Filardi, Attilio Olivieri, MD

Blood (2012) 120 (21): 4523.

https://doi.org/10.1182/blood.V120.21.4523.4523

Published: 2012

Journal Articles

Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Blood (2011) 118 (21): 317.

https://doi.org/10.1182/blood.V118.21.317.317

Published: 2011

Journal Articles

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, Enrica Morra

Blood (2011) 118 (15): 4079–4085.

https://doi.org/10.1182/blood-2011-05-351833

Published: 2011

Journal Articles

Mobilizing Chemotherapy Followed by G-CSF, Additioned by Plerixafor on Demand, Is Safe and Allows Both Adequate PBSC (Peripheral Blood Stem Cell) Collection and Safe ASCT (Autologous Stem Cell Transplantation) In Multiple Myeloma and Lymphoma Patients

Immacolata Attolico, Vincenzo Pavone, MD, MD, CH, Angelo Ostuni, Maurizio Musso, Alessandra Crescimanno, Massimo Martino, MD, Pasquale Iacopino, Giuseppe Milone, MD, Patrizia Tedeschi, Attilio Olivieri

Blood (2010) 116 (21): 2257.

https://doi.org/10.1182/blood.V116.21.2257.2257

Published: 2010

Journal Articles

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Marco Montillo, MD, Alessandra Tedeschi, Francesca Ricci, Alfonso Zaccaria, Monica Crugnola, Mauro Spriano, PierAngelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Angelo De Blasio, Eleonora Vismara, Enrica Morra, Valeria Belsito Petrizzi

Blood (2010) 116 (21): 1384.

https://doi.org/10.1182/blood.V116.21.1384.1384

Published: 2010

Journal Articles

Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis

Blood (2010) 116 (21): 861.

https://doi.org/10.1182/blood.V116.21.861.861

Published: 2010

Journal Articles

Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases.

Giuseppe Todeschini, MD, Paolo Corradini, MD, Sergio Cortelazzo, MD, Alessandro Rambaldi, MD, Andrea Gallamini, MD, Fabio Benedetti, MD, Andres Ferreri, MD, Attilio Olivieri, MD, Cristina Tecchio, MD, Massimiliano Bonifacio, MD, Niccolo Frungillo, MD, Claudia Castellino, MD, Andrea Rossi, MD, Chandrakala Toldo, MD, Roberto Crocchiolo, MD, Immacolata Attolico, MD, Giovanni Pizzolo, MD

Blood (2007) 110 (11): 4465.

https://doi.org/10.1182/blood.V110.11.4465.4465

Published: 2007

NARROW

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

JAK2 Negative Erythrocytosis Associated with JAK2 GGCC_46/1 Haplotype, Calr rs1049481_G, and Normal Erythropoietin Level: Is This a New Entity?

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning

Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Mobilizing Chemotherapy Followed by G-CSF, Additioned by Plerixafor on Demand, Is Safe and Allows Both Adequate PBSC (Peripheral Blood Stem Cell) Collection and Safe ASCT (Autologous Stem Cell Transplantation) In Multiple Myeloma and Lymphoma Patients

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis

Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only